Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23991233 | 0.87 | DPP4 (0.33) | KCNA5KMT2APOLBTDP1MEN1 | |
| SCHEMBL5656055 | 0.77 | KCNA5 (0.38) | KCNA5KMT2APOLBTDP1MEN1 | |
| SCHEMBL31729267 | 0.76 | KCNA5 (0.38) | KCNA5KMT2APOLBTDP1MEN1 | |
| SCHEMBL23989812 | 0.76 | KCNA5 (0.38) | KCNA5KMT2APOLBTDP1MEN1 | |
| SCHEMBL20139438 | 0.75 | KCNA5 (0.37) | KCNA5KMT2APOLBTDP1MEN1 | |
| SCHEMBL24768373 | 0.74 | — | — | |
| SCHEMBL1412434 | 0.74 | MAPK1 (0.40) | KCNA5KMT2AMEN1NPC1RAB9A | |
| SCHEMBL23991141 | 0.73 | KCNA5 (0.36) | KCNA5KMT2APOLBTDP1MEN1 | |
| SCHEMBL20139419 | 0.73 | KCNA5 (0.33) | KCNA5KMT2APOLBTDP1MEN1 | |
| SCHEMBL23985960 | 0.72 | ALDH1A1 (0.36) | KCNA5KMT2APOLBTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | KCNA5 2932/4885AKT1 3322/4885AKT2 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.